{"id":"hum0074","version":1,"url":"https://humandbs.dbcls.jp/research/hum0074/v1","datePublished":"2018-02-27","versions":[{"version":1,"datePublished":"2018-02-27"},{"version":2,"datePublished":"2018-09-25"}],"title":{"ja":"テーラーメイド治療を目指した肝炎ウイルスデータベース構築に関する研究","en":"Genome-wide association studies on Hepatitis C virus-related diseases and construction of genome database"},"summary":{"aims":{"ja":"テーラーメイド医療を目指した肝炎ウイルスデータベース構築","en":"Genome-wide association studies on Hepatitis C virus-related diseases and construction of genome database"},"methods":{"ja":"対象1〜3について、Affymetrix Genome-Wide Human SNP Array 6.0を使用して約90万個の一塩基多型（Single Nucleotide Polymorphisms：SNPs）の遺伝子型を決定後、ゲノムワイド関連解析（Genome-Wide Association Study：GWAS）を実施\n対象4について、Affymetrix Axiom Genome-Wide ASI 1 Array Plateを使用して約60万個のSNPsの遺伝子型を決定後、GWASを実施","en":"SNP-based genome-wide association studies"},"targets":{"ja":"1. PEG-IFN/RBVの治療応答性（血中C型肝炎ウイルス排除の有無）\nC型肝炎ウイルスRNAの陰性化が得られない群（null virological response［NVR］）：78症例\nC型肝炎ウイルスRNAの持続陰性を示す群（sustained virological response［SVR］）：51症例\nC型肝炎ウイルス応答群（virological response［VR］）一時的にでも陰性化した群（SVR + transient virologic response［TVR］群）：64症例\n2. C型肝炎PEG-IFN/RBV併用療法による血小板減少\n血小板減少＋：107症例\n血小板減少-：196症例\n3. 進展に伴うヘモグロビン減少\nヘモグロビン減少＋：94症例\nヘモグロビン減少-：209症例\n4. インターフェロン治療によるC型肝炎ウイルス排除（sustained virological response：SVR）後の肝発がん\n治療終了後1年以上経過して肝がんを発症した群：123症例\n治療終了後5年以上経過して肝がんを発症していない群：333症例","en":"1. virologic response to PEG-INF/RBV treatment\n78 null virologic response (NVR)\n64 virologic response (VR)\n51 sustained virologic response (SVR)\n2. decrease of PLT in response to PEG-IFN/RBV treatment\n107 HCV patients with decrease of PLT in response to PEG-IFN/RBV treatment\n196 HCV patients without decrease of PLT in response to PEG-IFN/RBV treatment\n3. Hb reduction\n94 HCV patients with Hb reduction\n209 HCV patients without Hb reduction\n4. hepatocellular carcinoma (HCC) development after eradication of HCV by IFN-based treatment\n123 patients who developed HCC at ≥1 year since the end of treatment\n333 patients who did not develop HCC at ≥5 years since the end of treatment"},"url":{"ja":null,"en":null}},"listingSummary":{},"releaseNote":{"ja":"以下の対象について、Affymetrix Genome-Wide Human SNP Array 6.0を使用して遺伝子型決定を行い、ゲノムワイド関連解析（Genome-Wide Association Study：GWAS）を実施した結果を提供する（cvs file）。\n1. C型肝炎ウイルス著効（血中C型肝炎ウイルス排除の有無）\nC型肝炎ウイルスRNAの陰性化が得られない群（null virological response［NVR］）：78症例\nC型肝炎ウイルスRNAの持続陰性を示す群（sustained virological response［SVR］）：51症例\nC型肝炎ウイルス応答群（virological response［VR］：SVR + transient virologic response［TVR］群）：64症例\n2. C型肝炎PEG-IFN/RBV併用療法による血小板減少\n血小板減少有：107症例\n血小板減少無：196症例\n3. 進展に伴うヘモグロビン減少\nヘモグロビン減少有：94症例\nヘモグロビン減少無：209症例","en":"A genome-wide association studies for following symptoms were performed by using of Affymetrix Genome-Wide Human SNP Array 6.0.\n(1) 78 null virologic response, 64 virologic response, and 51 sustained virologic response (43 SNPs)\n(2) 107 HCV patients with decrease of PLT in response to PEG-IFN/RBV treatment and 196 HCV patients without decrease of PLT in response to PEG-IFN/RBV treatment (66 SNPs)\n(3) 94 HCV patients with Hb reduction and 209 HCV patients without Hb reduction (32 SNPs)"},"dataProviders":[{"name":{"ja":"田中 靖人","en":"Yasuhito Tanaka"},"organization":{"name":{"ja":"熊本大学大学院 生命科学研究部 消化器内科学","en":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University"}}}],"researchProjects":[],"grants":[{"title":{"ja":"テーラーメイド治療を目指した肝炎ウイルスデーターベース構築に関する研究","en":"Construction of hepatitis virus related database aiming at personalized medicine"},"agency":{"ja":"厚生労働科学研究費補助金","en":"Grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan"},"grantIds":["H19-kanen-013"]},{"title":{"ja":"ウイルス性肝炎に対する応答性を規定する宿主因子も含めた情報のデータベース構築・治療応用に関する研究","en":"Database construction and therapeuitic applications including host genetic factors for hepatitis virus related diseases"},"agency":{"ja":"厚生労働科学研究費補助金","en":"Grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan"},"grantIds":["H22-kanen-005"]},{"title":{"ja":"肝炎の新規診断法や新規治療法を開発するためのゲノムワイド関連解析の手法を用いた宿主因子の解析に関する研究","en":"Genome-wide research on identification of host genetic factors to develop novel diagnostic and therapeutic methods for hepatitis."},"agency":{"ja":"厚生労働科学研究費補助金","en":"Grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan"},"grantIds":["JP15fk0210018"]},{"title":{"ja":"C型肝炎の新たな治療関連因子及び治癒後の病態進展・改善に関連する宿主因子等の同定を目指したゲノムワイド研究","en":"Genome-wide research for identification of host factors associated with liver disease progression or improvement after hepatitis C virus eradication."},"agency":{"ja":"日本医療研究開発機構（AMED） 肝炎等克服緊急対策研究事業","en":"Research Program on Hepatitis, Japan Agency for Medical Research and Development (AMED)"},"grantIds":["JP18fk0210001"]}],"relatedPublications":[{"title":"Genome-wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection","doi":"https://doi.org/10.1053/j.gastro.2017.01.041","datasets":["NHA000074"]},{"title":"Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C","doi":"https://doi.org/10.1038/ng.449","datasets":["NHA000064"]},{"title":"Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C","doi":"https://doi.org/10.1093/hmg/ddr249","datasets":["NHA000063","NHA000062"]}],"datasets":["NHA000064","NHA000063","NHA000062"],"controlledAccessUsers":[]}